2017
DOI: 10.1073/pnas.1616502114
|View full text |Cite
|
Sign up to set email alerts
|

Potent neutralization of hepatitis A virus reveals a receptor mimic mechanism and the receptor recognition site

Abstract: Hepatitis A virus (HAV) infects ∼1.4 million people annually and, although there is a vaccine, there are no licensed therapeutic drugs. HAV is unusually stable (making disinfection problematic) and little is known of how it enters cells and releases its RNA. Here we report a potent HAV-specific monoclonal antibody, R10, which neutralizes HAV infection by blocking attachment to the host cell. High-resolution cryo-EM structures of HAV full and empty particles and of the complex of HAV with R10 Fab reveal the ato… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

5
50
0

Year Published

2017
2017
2021
2021

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 45 publications
(55 citation statements)
references
References 50 publications
5
50
0
Order By: Relevance
“…First, it is possible that the quasi-enveloped capsid, which contains an 8-kDa extension on each of its 60 VP1 molecules ( 1 ), may differ structurally from the naked viral particle. Consistent with this, tandem YPX 3 L “late domains” present in VP2 that appear to interact with the ESCRT-associated protein ALIX during the process of quasi-envelopment are mostly buried below the surface of the X-ray structure of the naked HAV capsid ( 30 , 31 ). If their capsid structures do differ significantly, HAV and eHAV may interact with different receptors.…”
Section: Discussionmentioning
confidence: 55%
“…First, it is possible that the quasi-enveloped capsid, which contains an 8-kDa extension on each of its 60 VP1 molecules ( 1 ), may differ structurally from the naked viral particle. Consistent with this, tandem YPX 3 L “late domains” present in VP2 that appear to interact with the ESCRT-associated protein ALIX during the process of quasi-envelopment are mostly buried below the surface of the X-ray structure of the naked HAV capsid ( 30 , 31 ). If their capsid structures do differ significantly, HAV and eHAV may interact with different receptors.…”
Section: Discussionmentioning
confidence: 55%
“…Crystals of SCARB2-JL2 complex diffracted to 3.5 Å, belonging to the space group C2, and the crystals contained two complex molecules in the asymmetric unit with a solvent content of 58% (corresponding to a Matthews coefficient VM = 2.7 Å 3 ·Da −1 ) (Matthews, 1968 ). The complex structure was determined using the molecular replacement method based on the combination of the models of SCARB2 at neutral pH (PDB code: 4TW2) (Dang et al, 2014 ) and the mouse Fab (PDB code: 5WTG) (Wang et al, 2017 ). The final refined complex model had reasonable R-factors and very good stereochemistry.…”
Section: Resultsmentioning
confidence: 99%
“…The data sets were processed and scaled using the HKL2000 package (Otwinowski and Minor, 1997 ). The initial structure solutions of the SCARB2-Fab complex were obtained by molecular replacement using the program Phaser v2.1 (McCoy et al, 2007 ) with the crystal structure of SCARB2 (PDB code: 4TW2) (Dang et al, 2014 ) and the mouse Fab structure (Wang et al, 2017 ) (PDB code: 5WTG) as a search template. Manual model building and refinement were performed using COOT (Emsley and Cowtan, 2004 ) and PHENIX (Adams et al, 2010 ) following rigid body refinement, energy minimization, B-factor refinement, and group NCS constraints.…”
Section: Methodsmentioning
confidence: 99%
“…In contrast to canyon epitopes, 3- and 2-fold plateau epitopes are not within or adjacent to known receptor binding sites, although antibodies targeting these epitopes neutralize viral infectivity prior to virus attachment. It is possible that these epitopes are in the neighborhood of as-yet unidentified receptor-binding sites; 62 however, this neutralization may involve an alternative mechanism 63 , 64 .…”
Section: Discussionmentioning
confidence: 99%